Codexis to Report Third Quarter 2024 Financial Results on October 31
Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, has announced that it will report its financial results for the third quarter of 2024 on Thursday, October 31, 2024, after market close. The company's management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the financial results and provide a business update.
Investors and interested parties can access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. For those who prefer to join by phone, the live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), using access ID #13726635.
Codexis, Inc. (NASDAQ: CDXS), un importante fornitore di soluzioni enzimatiche per una produzione terapeutica efficiente e scalabile, ha annunciato che riferirà i suoi risultati finanziari per il terzo trimestre del 2024 giovedì 31 ottobre 2024, dopo la chiusura del mercato. Il management dell'azienda ospiterà una telefonata e webcast alle 16:30 ora orientale per discutere i risultati finanziari e fornire un aggiornamento sull'attività.
Gli investitori e le parti interessate possono accedere al webcast dal vivo sul sito web delle Relazioni con gli Investitori di Codexis, dove sarà archiviato per 90 giorni. Per coloro che preferiscono partecipare telefonicamente, la chiamata dal vivo può essere raggiunta componendo il numero 877-705-2976 (nazionale) o 201-689-8798 (internazionale). Una registrazione telefonica della chiamata sarà disponibile per 48 ore componendo il numero 877-660-6853 (nazionale) o 201-612-7415 (internazionale), utilizzando l'ID di accesso #13726635.
Codexis, Inc. (NASDAQ: CDXS), un proveedor líder de soluciones enzimáticas para la fabricación terapéutica eficiente y escalable, ha anunciado que reportará sus resultados financieros para el tercer trimestre de 2024 el jueves 31 de octubre de 2024, después del cierre del mercado. La dirección de la compañía llevará a cabo una llamada de conferencia y webcast a las 4:30 p. m. Hora del Este para discutir los resultados financieros y proporcionar una actualización empresarial.
Los inversores y partes interesadas pueden acceder al webcast en vivo en el sitio web de Relaciones con Inversores de Codexis, donde se archivará durante 90 días. Para aquellos que prefieren unirse por teléfono, la llamada en vivo se puede acceder marcando 877-705-2976 (nacional) o 201-689-8798 (internacional). Una repetición telefónica de la llamada estará disponible durante 48 horas marcando 877-660-6853 (nacional) o 201-612-7415 (internacional), usando el ID de acceso #13726635.
Codexis, Inc. (NASDAQ: CDXS)는 효율적이고 확장 가능한 치료제 제조를 위한 효소 솔루션의 선도적인 제공업체로, 2024년 3분기 재무 결과를 2024년 10월 31일 목요일 시장 종료 후 발표할 것이라고 발표했습니다. 회사의 경영진은 동부 표준시 오후 4시 30분에 재무 결과를 논의하고 비즈니스 업데이트를 제공하기 위한 컨퍼런스 콜 및 웹캐스트를 주최할 것입니다.
투자자 및 이해 관계자는 90일 동안 아카이브되는 Codexis 투자자 관계 웹사이트에서 실시간 웹캐스트에 접속할 수 있습니다. 전화로 참여하고자 하는 분들을 위해 실시간 전화는 877-705-2976 (국내) 또는 201-689-8798 (국제)로 전화를 걸어 접근할 수 있습니다. 전화 재생은 877-660-6853 (국내) 또는 201-612-7415 (국제)로 전화하여 엑세스 ID #13726635를 사용하면 48시간 동안 제공됩니다.
Codexis, Inc. (NASDAQ: CDXS), un fournisseur de solutions enzymatiques de premier plan pour une fabrication thérapeutique efficace et évolutive, a annoncé qu'elle publiera ses résultats financiers pour le troisième trimestre de 2024 le jeudi 31 octobre 2024, après la fermeture des marchés. La direction de la société animera un appel conférence et un webcast à 16h30, heure de l'Est, pour discuter des résultats financiers et fournir une mise à jour commerciale.
Les investisseurs et parties intéressées peuvent accéder au webcast en direct sur le site des Relations avec les Investisseurs de Codexis, où il sera archivé pendant 90 jours. Pour ceux qui préfèrent participer par téléphone, l'appel en direct peut être rejoint en composant le 877-705-2976 (domestique) ou le 201-689-8798 (international). Une rediffusion téléphonique de l'appel sera disponible pendant 48 heures en composant le 877-660-6853 (domestique) ou le 201-612-7415 (international), en utilisant l'identifiant d'accès #13726635.
Codexis, Inc. (NASDAQ: CDXS), ein führender Anbieter von enzymatischen Lösungen für die effiziente und skalierbare Herstellung therapeutischer Produkte, hat angekündigt, dass es am Donnerstag, den 31. Oktober 2024, nach Börsenschluss seine Finanzergebnisse für das dritte Quartal 2024 berichten wird. Die Unternehmensleitung wird um 16:30 Uhr Eastern Time eine Konferenzschaltung und einen Webcast abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Investoren und interessierte Parteien können auf den lebenden Webcast auf der Seite für Investor Relations von Codexis zugreifen, wo dieser 90 Tage lang archiviert wird. Für diejenigen, die lieber telefonisch teilnehmen möchten, kann die Live-Schaltung über die Nummer 877-705-2976 (inländisch) oder 201-689-8798 (international) erreicht werden. Eine Telefonwiederholung der Schaltung ist für 48 Stunden unter der Nummer 877-660-6853 (inländisch) oder 201-612-7415 (international) verfügbar, unter Verwendung der Zugangs-ID #13726635.
- None.
- None.
REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on Thursday, October 31, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule and nucleic acid therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
FAQ
When will Codexis (CDXS) report its Q3 2024 financial results?
How can investors access Codexis' (CDXS) Q3 2024 earnings call?
Will there be a replay available for Codexis' (CDXS) Q3 2024 earnings call?
What is Codexis' (CDXS) primary business focus?
